PharmaBoardroom

Interview with John Chalmers, Senior Director, The George…

For those that are not familiar with your name, would you start by introducing yourself? After obtaining my PhD in cardiovascular physiology I moved…

Interview with Megan Fookes, Director, Rare Voices

Rare Voices Australia is a new organisation that has been established after the national rare diseases symposium in 2011. Can you please begin with…

Interview with John C W Lim, CEO, Health Sciences Authority

HSA celebrated its 10th anniversary in 2011. How different is the organisation today from when it started? HSA covers the regulation of health…

Interview with Alfred Grün, Managing Director, Schülke &…

2012 represents the 123rd anniversary of Schülke&Mayr. There have been many changes over the years, but do you think the ideals and values of…

Interview with Simranjit Singh, Chairman, BioSingapore

In addition to being the director of strategic planning at Quintiles you are also the Chairman of BioSingapore. In this context, can you please…

Interview with Jean-Luc Lowinski, Senior Vice President, Asia…

Among Big Pharma, Sanofi has a track record of placing a lot of faith in emerging markets – with local production, a large product portfolio,…

Interview with Orison Huerta, Managing Director Mexico, Central…

Can you give us a historical overview of the main milestones and achievements of Ottobock since it settled in Mexico in 1995? Ottobock was founded…

Australia: Where Value Beats Cost

In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is going through globally: the…

Interview with Jaime Cervantes Covarrubias, General Manager,…

Can you give us a historical overview of the company and tell us about the vision behind its creation? Vitalmex is a very humanistic company that…

Interview with Eduardo Gonzalez Pier, Financial Director, IMSS…

IMSS is a central pillar in the Mexican healthcare system, covering all Mexicans working for the declared formal private sector. How do you assess the…

Interview with David Gallagher, Managing Director, Pfizer Ireland

You noted that, in the ‘old days’, the pharma business had the following characteristics: first of all, it was a molecule-driven business,…

Interview with Ambrose McLoughlin, Secretary General, Department…

Dr. McLoughlin, you were appointed to your post in April of this year. Can you please give us an impression of what you inherited at this Department…

Tagged with